The company, founded by 25-year-old Kian Sadeghi, announced a $14 million Series A, bringing its total funding to about $32 million.
The global cancer genetic testing market size was valued at USD 6.70 billion in 2024 and is projected to reach from USD 7.47 billion in 2025 to USD 17.98 billion by 2033, growing at a CAGR of 11.6% ...
Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...